{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-039694","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.486676+00:00","generated_at":"2026-05-22T17:55:55.966977+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aditxt subsidiary Adimune reports positive preclinical data for ADI-100; clinical trials planned in Germany and US","bullets":["Completed toxicology, bio-distribution, persistence, and antibody formation studies for ADI-100 with no safety flags.","Ex vivo data from human patient cells showed ADI-100 down-regulates anti-GAD immune activity, supporting clinical advancement.","IP portfolio includes 130-150 patents/applications protecting the ADI platform as a tolerance delivery system.","Clinical studies planned: psoriasis and type 1 diabetes in Germany; stiff-person syndrome and neurological in US.","ADI-100 aims to restore immune tolerance using apoptotic cells and modified antigen (GAD), not general immune suppression."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-039694","json":"https://secwatch.observer/filing/0001213900-25-039694.json","markdown":"https://secwatch.observer/filing/0001213900-25-039694.md","text":"https://secwatch.observer/filing/0001213900-25-039694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025039694/0001213900-25-039694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025039694/ea0240881-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T17:55:55.966977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}